MSLE — Satellos Bioscience Inc. Common Stock

MSLE closed at $6.54 (+1.87%) on Oct 26, 2026. Float: 18.2M shares. Latest SEC filing: 6-K on Oct 27, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for MSLE in the TickerWise workspace.

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki on July 27, 2012 and is headquartered in Toronto, Canada.

Company profile

• Sector: Healthcare
• Industry: Medical - Pharmaceuticals
• Country: CA
• Exchange: NASDAQ
• Employees: 14
• Website: http://www.satellos.com

Latest SEC filings for MSLE

• 2026-10-276-K
• 2026-10-216-K
• 2026-10-056-K
• 2026-09-306-K
• 2026-09-246-K
• 2026-09-156-K
• 2026-09-096-K
• 2026-09-016-K
• 2026-08-136-K
• 2026-07-086-K

Latest MSLE news

• 2026-10-21Satellos to Participate in Upcoming Investor Conferences Read article
• 2026-09-28Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages Read article

Related companies

• ONC — BeOne Medicines Ltd.
• LQDA — Liquidia Corporation
• DFTX — Definium Therapeutics, Inc.
• AVLN — Avalyn Pharma Inc. Common Stock
• LTGO — Latigo Biotherapeutics Inc.
• LFMDP — LifeMD, Inc.
• CGEM — Cullinan Therapeutics, Inc.
• CUVL — Clinuvel Pharmaceuticals Ltd.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.